Anti-CD44v9 Antibody-drug Conjugate AMT-116 clinical trials
Also written AMT-116.
Its developmentBy Multitude Therapeutics and Imunopharm Technology, step by step5 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.How each study uses Anti-CD44v9 Antibody-drug Conjugate AMT-116 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-CD44v9 Antibody-drug Conjugate AMT-116 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- AMT-116
- 4
Studies by the year they started
5 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Multitude Therapeutics Inc. (4) · Beijing Immunochina Medical Science & Technology Co., Ltd. (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test Anti-CD44v9 Antibody-drug Conjugate AMT-116.
- Dec 2026AMT-116 in Patients With Advanced Solid TumorsPhase 1 · Multitude Therapeutics Inc.
- May 2027AMT-116 in Combination With AK112 in Patients With Lung CancerPhase 1/2 · Multitude Therapeutics Inc.
Studies
Open first, then newest update. How each study uses Anti-CD44v9 Antibody-drug Conjugate AMT-116 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 ImmunotherapyRecruitingPhase 2/3Multitude Therapeutics Inc.NCT07718737Written as AMT-116How we know
- AMT-116 in Combination With AK112 in Patients With Lung CancerRecruitingPhase 1/2Multitude Therapeutics Inc.NCT07590531Written as AMT-116How we know
- AMT-116 in Patients With Advanced Solid TumorsRecruitingPhase 1Multitude Therapeutics Inc.NCT05725291Written as AMT-116How we know
- AMT-116 in Patients with Solid TumorsRecruitingPhase 1/2Multitude Therapeutics Inc.NCT06782334Written as AMT-116How we know
- Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced TumorsStatus unknownPhase 1/2Beijing Immunochina Medical Science & Technology Co., Ltd.NCT05117138Written as AMT-116 CAR-T cellsHow we know
What changed recently
From the registry's own updates since Oct 20, 2026.